Sarissa Capital Acquisition Corp. (SRSAU) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting the healthcare and biopharmaceutical industry in the United States and other developed countries; it offers no current operational products or services beyond this acquisition vehicle structure, which provides capital infusion, strategic guidance, and public market access to target companies via de-SPAC transactions. The company, incorporated in 2020 and headquartered in Greenwich, Connecticut, raised $175 million in its initial public offering in October 2020 through 17.5 million units at $10 each, consisting of one Class A ordinary share and one-third of a warrant exercisable at $11.50, with Cantor Fitzgerald as sole bookrunner and an over-allotment option exercised for an additional 2.5 million units. Sarissa Capital Acquisition Sponsor LLC, capitalized by funds managed by Sarissa Capital Management LP, serves as sponsor; led by Chairman and CEO Dr. Alexander John Denner Ph.D., founding partner and CIO of the activist hedge fund sponsor. In its major recent development, the company announced in October 2022 that it would not complete an initial business combination within the required timeframe under its amended articles of association, leading to redemption of all outstanding Class A ordinary shares effective October 31, 2022, at a pro rata trust distribution of approximately $10.05 per share to shareholders within 10 business days thereafter; trading of units (SRSAU), shares (SRSA), and warrants (SRSAW) ceased following liquidation, with no subsequent mergers, acquisitions, or operational shifts reported as of late 2025.